Most Active Volume Stock: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
- Author: Zachary Reyes Mar 18, 2017,
Mar 18, 2017, 8:37
In the transaction dated December 19, 2016, the great number of shares disposed came courtesy the Senior Vice President and CFO; STAAB THOMAS R II disposed a total of 3,250 shares at an average price of $7.45, amounting to approximately $24,213. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. (NASDAQ:BCRX) previous 52-week high was $8.86 and moved up 232.58% over the same period, trading at a volume of 6.27 million. (NASDAQ:BCRX) which led to swings in the share price.
Over the past five trading sessions shares of ImmunoGen, Inc. This insider owns 124,187 BCRX shares, amounting to about $1,038,203 as of recent trading price which is 29.29% above its 20-day moving average and 71.89% above its 50-day moving average. That puts the market capitalization at $634.38 mln. (NASDAQ:BCRX) traded with the volume of 6.27 Million in the previous trading session.
The Stock had a 2 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 2 and 2.22 respectively. According to their observations and findings, the stock could provide a high EPS of $-0.14/share and a Low EPS of $-0.2/share. "8" Analysts are saying that the company to report next quarterly earnings of $-0.17 per share for period Quarter Ending_Jun-17. During the same quarter in the prior year, the firm earned ($0.25) EPS.
BioCryst Pharmaceuticals, Inc. on 02/27/2017 reported its EPS as $-0.06 with the analysts projecting the EPS of the stock as $-0.23.
Many research firms have provided their ratings on BioCryst Pharmaceuticals, Inc. (BCRX). The consensus rating is 2.3, suggesting the market has given up on the stock. If you are reading this story on another domain, it was illegally copied and republished in violation of worldwide trademark & copyright laws. Compiling all of the recommendations for the firm, BioCryst Pharmaceuticals, Inc. Finally, Trexquant Investment LP bought a new position in BioCryst Pharmaceuticals during the fourth quarter valued at about $231,000. RTW Investments LLC raised its position in shares of BioCryst Pharmaceuticals by 88.0% in the third quarter. The company reported its last quarter on Dec 16.
Zacks offers analysts with an Average Broker Rating (or ABR), basing it on sell-side recommendations. Renaissance Technologies LLC bought a new position in shares of BioCryst Pharmaceuticals during the fourth quarter worth approximately $316,000.
A number of hedge funds and other institutional investors have recently modified their holdings of the company.
These are 1 Hold Rating, 6 Buy Ratings. FBR & Co reaffirmed an "outperform" rating on shares of BioCryst Pharmaceuticals in a research note on Monday, January 23rd.
Amid volatile financial markets and the presidential election, various investment brokerages have made amendments to their price targets and ratings on shares of BioCryst Pharmaceuticals, Inc. Finally, Ladenburg Thalmann Financial Services began coverage on shares of BioCryst Pharmaceuticals in a report on Thursday, February 16th. They issued a "buy" rating and a $11.00 price objective for the company.
To view the price target ranked by analysts, BSX attains high-level price target of 30 while lower level target was 20, it can be use an indication to know how much worth stock has stored in it. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. HC Wainwright restated a "buy" rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a report on Wednesday, March 1st.